Investigation of ceftriaxone-resistant *Neisseria gonorrhoeae* detected in Scotland, 2018-2024

Martin P McHugh[1,2,3]*, Kirsty Aburajab[4], Alexandra Maxwell[5], John Anderson[1], Fraser Cairns[1], Seb Cotton[1,2], Andrew Gough[1], Brian Malloy[1], Katharine Mathers[1], Lynne Renwick[1], Jill Shepherd[1], Kate E Templeton[1,2]

[1]NHS Lothian, Edinburgh, United Kingdom
[2]Edinburgh Medical School, University of Edinburgh, Edinburgh, United Kingdom
[3]School of Medicine, University of St Andrews, St Andrews, United Kingdom
[4]NHS Forth Valley, Falkirk, United Kingdom
[5]NHS Greater Glasgow and Clyde, Glasgow, United Kingdom

*Corresponding author: Martin P McHugh, v1mmchug@ed.ac.uk
ORCID: 0000-0002-0370-3700

ABSTRACT

Objectives: Describe the clinical, phenotypic, and genomic characteristics of ceftriaxone-resistance *Neisseria gonorrhoeae* from Scotland

Methods: Cases were identified in routine care from 2018-2024. Minimum inhibitory concentrations were determined for seven antimicrobial agents. Whole genome sequencing was performed with Illumina and Oxford Nanopore Technology instruments. A phylogeny containing global ceftriaxone-resistant genomes was generated with Parsnp. A collection of ST8780 genomes was also analysed to give further context using reference based mapping with Snippy.

Results: There were five cases of ceftriaxone-resistant *N. gonorrhoeae* detected. One case (MLST ST1903) clustered within the FC428 lineage in a returning traveller from an Asia-Pacific country. Two cases belonged to the recently described extensively drug resistant MLST ST16406, a returning traveller from an Asia-Pacific country and a sexual contact within

Scotland. The final two cases were a resident of an Asia-Pacific country and a sexual contact within Scotland, both belonged to MLST ST8780. These were distinct from other publicly available ST8780 genomes suggesting a novel introduction of the mosaic *penA* 60.001 allele. All cases were initially treated with ceftriaxone-based regimes, four returned for test of cure and showed clearance of infection.

Conclusions: As ceftriaxone resistance is increasingly identified, multiple public health interventions are required to reduce the impact of resistance on gonorrhoea treatment globally.

59 **INTRODUCTION**

60

61 *Neisseria gonorrhoeae* is a leading cause of sexually transmitted infections globally. WHO
62 includes *N. gonorrhoeae* on the list of Priority Pathogens due to significant antimicrobial
63 resistance (AMR), reflecting the significant global health challenge posed by this pathogen [1].
64 Currently, ceftriaxone is the backbone of gonorrhoeae treatment. Ceftriaxone resistance has
65 been increasingly identified particularly associated with countries in the Asia-Pacific region, and
66 in recent years extensively drug-resistant (XDR) cases with few treatment options have been
67 described [2–5].

68

69 We describe the identification, clinical management, laboratory, and genomic investigation of
70 five ceftriaxone-resistant *N. gonorrhoeae* isolated in Scotland.

71

72 **MATERIALS AND METHODS**

73

74 This study describes five cases of ceftriaxone-resistant *N. gonorrhoeae* identified in Scotland as
75 part of routine surveillance undertaken by the Scottish Bacterial Sexually Transmitted Infections
76 Reference Laboratory between 2018-2024. All *N. gonorrhoeae* isolates were submitted by
77 regional diagnostic laboratories for antimicrobial sensitivity testing (AST) and further
78 characterisation. Species identification was confirmed with biochemical testing and MALDI-TOF
79 (Bruker). AST was performed by agar incorporation and Etest strips (BioMerieux), minimum
80 inhibitory concentrations (MICs) were interpreted with EUCAST v14.0 breakpoints. Genomic
81 DNA was extracted from culture suspensions, short read libraries were prepared with the
82 Illumina DNA Prep kit and sequenced on a MiSeq or NextSeq 2000 (Illumina). Short reads were
83 trimmed with Trimmomatic v0.39 and assembled with SPAdes v3.15.5 (with the --isolate and --
84 cov-cutoff 15 options). PyngoST was used to perform multilocus sequencing typing (MLST) and
85 *N. gonorrhoeae* sequence typing for antimicrobial resistance (NG-STAR). Resistance markers
86 were identified from assemblies using PathogenWatch. Published sequences from ceftriaxone-
87 resistant *N. gonorrhoeae* were used for global context (Table S1), a core genome alignment was

88 generated and recombination masked with Parsnp v1.5.3, and the phylogeny visualised with
89 iTOL v6. To further investigate ST8780, short reads were downloaded from the NCBI Short Read
90 Archive (Table S2), trimmed, mapped to the WHO O reference genome (Accession
91 NZ_CP145037.1) with Snippy v4.6.0, recombination masked with Gubbins v2.4.1, and the
92 resulting phylogeny visualised with iTOL. Long reads were generated for SGC-24-001 and SGC-
93 24-002 using the Rapid Barcoding v14 library preparation kit and an R10.4.1 flowcell on a
94 GridION sequencer with super high accuracy basecalling in MinKNOW v24.02.16. Long reads
95 were quality filtered with Filtlong v0.2.1 and assemblies generated with Flye v2.9.3 (with the --
96 nano-hq and --genome-size 2.3m options). Resulting assemblies were polished with Medaka
97 v1.11.3, Polypolish v0.6.0, and Pypolca 0.3.1. Patient demographics and treatment histories
98 were retrieved from electronic health records.
99
100
101 **RESULTS**
102 **Case 1, SGC-23-001**
103
104 Case 1 (SGC-23-001) was a male who presented to sexual health services in 2018 with urethral
105 discharge after unprotected sex in an Asia-Pacific country (Table S3). Urine was NAAT positive
106 for *N. gonorrhoeae* and a urethral swab grew *N. gonorrhoeae*. The patient was given a 500mg
107 intramuscular dose of ceftriaxone and 1g oral azithromycin as per national treatment guidance
108 at the time. Fourteen days after empirical treatment AST results were reported which showed
109 multidrug resistance including ceftriaxone (MIC 0.75 mg/L) and cefixime (MIC 2.0 mg/L), but not
110 azithromycin (MIC 0.25 mg/L) and the patient was given a further 2g oral dose of azithromycin
111 (Table S4). Test of cure (TOC) NAAT was negative. No sexual contacts within Scotland were
112 identified.
113
114 **Case 2, SGC-23-002**
115

116 The second case (SGC-23-002) was a male who presented to sexual health services in 2022 with
117 a two week history of urethral discharge and dysuria after unprotected sex in an Asia-Pacific
118 country (Table S3). The urine NAAT was positive, and *N. gonorrhoeae* was grown from a
119 urethral swab. Intramuscular ceftriaxone (1g) was given, and the patient had a negative TOC
120 two weeks later. AST identified this as an XDR strain with non-susceptibility to six of the seven
121 tested agents, including ceftriaxone (MIC 0.19 mg/L), cefixime (2.0 mg/L), and high level
122 resistance to azithromycin (MIC >256.0 mg/L; Table S4).
123
124 **Case 3, SGC-23-003**
125
126 Case 3 (SGC-23-003) was a female sexual contact of case 2 in Scotland, case 2 and 3 reported no
127 other recent sexual contacts (Table S3). The patient reported two days of abdominal pain, on
128 examination profuse discharge was found but no evidence of pelvic inflammatory disease. A
129 vaginal swab was NAAT positive and *N. gonorrhoeae* was isolated from a cervical swab.
130 Intramuscular ceftriaxone (1g) was given, and the patient had a negative TOC two weeks later.
131 AST results were similar to case 2 although the ceftriaxone MIC was slightly higher (MIC 0.38
132 mg/L; Table S4).
133
134 **Case 4, SGC-24-002**
135
136 Case 4 (SGC-24-002) was an asymptomatic female who tested NAAT positive on a vaginal swab
137 after unprotected sex in 2024 (Table S3). The patient was treated with intramuscular
138 ceftriaxone (1g) and was negative at TOC. AST showed multidrug resistance including
139 ceftriaxone (MIC 0.75 mg/L) and cefixime (MIC 2.0 mg/L; Table S4). Only one sexual partner was
140 identified.
141
142 **Case 5, SGC-24-001**
143

144 Case 5 (SGC-24-001) was the male sexual contact of case 4 in Scotland. Case 5 reported two
145 other female sexual contacts, but these individuals could not be traced for testing (Table S3).
146 Case 5 reported dysuria and urethral discharge for one week prior to presentation. The urine
147 NAAT was positive, and *N. gonorrhoeae* was grown from a urethral swab. AST showed the same
148 multidrug resistance as case 4 with slightly higher cephalosporin MICs (ceftriaxone MIC 1.0
149 mg/L and cefixime MIC 3.0 mg/L; Table S4). Intramuscular ceftriaxone (1g) was given at
150 presentation, when culture results were reported the patient was further treated with
151 intramuscular gentamicin (240mg) and oral azithromycin (2g). The patient was a resident of an
152 Asia-Pacific country and moved back before TOC was performed, further follow-up has been
153 unsuccessful.
154
155 **Genomic investigation**
156
157 Genotypic mechanisms conferring all detected phenotypic resistance were identified in the
158 genomes, including the mosaic *penA*-60.001 conferring cephalosporin resistance, *gyrA* and *parC*
159 mutations conferring ciprofloxacin resistance, and the *rpsJ* V57M polymorphism and *tetM*
160 conferring tetracycline resistance (Table S5). The isolates belonged to diverse sequence types
161 which suggested distinct origins. Phylogenetic analysis with a background of international
162 ceftriaxone-resistant isolates revealed that SGC-23-001 clustered within a diverse clade
163 containing MLST ST1903 and related STs identified in 2015-2021 from China and five other
164 countries (Figure 1). SGC-23-001 was also assigned to NG-STAR ST233 which was common in
165 this clade, indicating the presence of similar AMR mechanisms. The closest match in this
166 dataset was the FC428 type strain from Japan in 2015 (428 single nucleotide polymorphisms
167 [SNPs]). SGC-23-002 and SGC-23-003 differed from each other by two SNPs, consistent with
168 direct transmission as supported by partner notification. Additionally, the two genomes
169 differed by a median of 4 SNPs (range 1-7 SNPs) to three other MLST ST16406 and NG-STAR
170 ST4465 genomes identified in Austria, England, and France in 2022 (Figure 1). High-level
171 azithromycin resistance was conferred by the 23S rDNA A2059G mutation (*Escherichia coli*
172 numbering). No SNPs were identified between SGC-24-001 and SGC-24-002 which supports

173 direct transmission. Additionally, these two genomes were distinct in this analysis differing to
174 the nearest genome (GD2021236 from China in 2021) by 3430 SNPs. SGC-24-001 and SGC-24-
175 002 were assigned to MLST ST8780 and NG-STAR ST5998, this was a novel NG-STAR ST
176 indicating these genomes are unique within the global database. To further investigate the
177 origins of SGC-24-001 and SGC-24-002, a collection of MLST ST8780 genomes were identified
178 and a phylogeny generated (Figure S1). The Scottish isolates were the only ones containing the
179 mosaic *penA*-60.001 allele, indicating that this is a novel acquisition of ceftriaxone resistance in
180 this ST. The Scottish isolates were most closely related to an isolate from Thailand in 2018 (949
181 SNPs). SGC-24-001 and SGC-24-002 carried the cryptic plasmid, conjugative plasmid, and the
182 African-type β-lactamase (bla_{TEM-1}) plasmid.
183



Figure 1 Maximum-likelihood phylogeny of five Scottish and 62 international ceftriaxone-resistant *N. gonorrhoeae.* Scottish genomes are highlighted in purple. Metadata bars coloured as per figure legend.

DISCUSSION

192 We describe five cases of ceftriaxone-resistant *N. gonorrhoeae* acquired in, or involving
193 residents of, Asia-Pacific countries identified in Scotland. Case 1 from 2018 belonged to the
194 FC428-related clone (MLST ST1903) which has acquired the mosaic *penA* allele and is frequently
195 identified in the Asia-Pacific [4]. Cases 2 and 3 from 2022 belonged to ST16406 and were
196 resistant to current first-line antimicrobial agents ceftriaxone, azithromycin, and ciprofloxacin.
197 ST16406 was first described in 2022 and has been identified in travellers returning from the
198 Asia-Pacific region to Austria, England, and France [2,3,5]. We identified a median of 4 SNPs
199 between cases identified in Austria, England, France, and Scotland which reflects the short
200 collection time (all in 2022) but also suggests a rapidly spreading clone. To our knowledge,
201 cases 4 and 5 are the first ST8780 identified with ceftriaxone resistance. ST8780 belongs to the
202 generally antimicrobial-susceptible genomic lineage B of *N. gonorrhoeae*, indicating that mosaic
203 *penA* 60.001 is spreading further within the global population as recently identified by
204 Golparian *et al* [6]. Concerningly, Case 5 reported two sexual contacts who could not be traced
205 and may lead to further ceftriaxone-resistant cases within Scotland.
206 Four patients were successfully treated with ceftriaxone-based regimes despite *in vitro*
207 resistance, the remaining patient did not return for TOC. There is growing evidence that the
208 ceftriaxone resistance breakpoint is too low for genital infections, although treatment success
209 at other sites such as the oropharynx need to be considered in any breakpoint change [7–9].
210 We also identified different cephalosporin MICs within two transmission pairs, although the
211 reported values are within the expected variability of the method (± two doubling dilutions).
212 Our reliance on cultured isolates is a potential limitation as ~50% of gonorrhoea cases in
213 Scotland are diagnosed by NAAT only and no isolate is available. It is possible that culture-
214 negative ceftriaxone resistant cases have occurred that would not be included in our study. To
215 reduce the impact of this, patients that remain symptomatic after treatment are reviewed to
216 ascertain if ceftriaxone resistance may be present.
217
218
219 **CONCLUSION**
220

Resistance to ceftriaxone poses a significant risk to *N. gonorrhoeae* treatment guidelines globally, although in the cases described here who had TOC first line agents were successful. Efforts to expand access to rapid molecular diagnostics to determine sensitivity to ceftriaxone and alternative agents are required to reduce the selection of resistance, and the introduction of novel therapeutic agents must be carefully managed and combined with robust surveillance to identify emerging resistance. The 4CMenB vaccine has been approved in the UK for individuals at high risk of gonorrhoea, the effect of this vaccine on infections and AMR should be closely monitored. Finally, sustained messaging to reduce STI transmission both domestically and in international travellers should be prioritised.

ETHICS STATEMENT

Ethical approval for this work was granted by the Lothian National Research Scotland BioResource (Reference 20/ES/0061)

COMPETING INTERESTS

None declared

FUNDING STATEMENT

This work was funded by NHS National Services Scotland via the Scottish Bacterial Sexually Transmitted Infections Reference Laboratory

DATA AVAILABILITY STATEMENT

Sequence data has been uploaded to the European Nucleotide Archive (BioProject PRJEB73456)

ACKNOWLEDGEMENTS

We would like to thank Matthew Holden, Sharif Shaaban, and Lesley Wallace for providing feedback on the manuscript. We thank diagnostic microbiology laboratories for providing isolates for characterisation.

CONTRIBUTIONS

MPM: conceptualisation, methodology, data curation, investigation, writing – original draft, guarantor; KA, AM, JA, FC, SC, AG, BM, KM, LR and JS: data curation, writing – review and editing; KET: conceptualisation, writing – review and editing

REFERENCES

1 WHO. WHO Bacterial Priority Pathogens List, 2024: bacterial pathogens of public health importance to guide research, development and strategies to prevent and control antimicrobial resistance. Geneva, Switzerland: World Health Organisation 2024.

2 Maubaret C, Caméléna F, Mrimèche M, *et al.* Two cases of extensively drug-resistant (XDR) Neisseria gonorrhoeae infection combining ceftriaxone-resistance and high-level azithromycin resistance, France, November 2022 and May 2023. *Eurosurveillance*. 2023;28:2300456. doi: 10.2807/1560-7917.ES.2023.28.37.2300456

3 Day M, Pitt R, Mody N, *et al.* Detection of 10 cases of ceftriaxone-resistant Neisseria gonorrhoeae in the United Kingdom, December 2021 to June 2022. *Eurosurveillance*. 2022;27:2200803. doi: 10.2807/1560-7917.ES.2022.27.46.2200803

280 4 Tang Y, Liu X, Chen W, *et al.* Antimicrobial Resistance Profiling and Genome Analysis of the
281 penA-60.001 Neisseria gonorrhoeae Clinical Isolates in China in 2021. *J Infect Dis*.
282 2023;228:792–9. doi: 10.1093/infdis/jiad258

283 5 Pleininger S, Indra A, Golparian D, *et al.* Extensively drug-resistant (XDR) Neisseria
284 gonorrhoeae causing possible gonorrhoea treatment failure with ceftriaxone plus
285 azithromycin in Austria, April 2022. *Eurosurveillance*. 2022;27:2200455. doi: 10.2807/1560-
286 7917.ES.2022.27.24.2200455

287 6 Golparian D, Vestberg N, Södersten W, *et al.* Multidrug-resistant Neisseria gonorrhoeae
288 isolate SE690: mosaic penA-60.001 gene causing ceftriaxone resistance internationally has
289 spread to the more antimicrobial-susceptible genomic lineage, Sweden, September 2022.
290 *Eurosurveillance*. 2023;28:2300125. doi: 10.2807/1560-7917.ES.2023.28.10.2300125

291 7 Eyre DW, Sanderson ND, Lord E, *et al.* Gonorrhoea treatment failure caused by a Neisseria
292 gonorrhoeae strain with combined ceftriaxone and high-level azithromycin resistance,
293 England, February 2018. *Eurosurveillance*. 2018;23:1800323. doi: 10.2807/1560-
294 7917.ES.2018.23.27.1800323

295 8 Unemo M, Golparian D, Oxelbark J, *et al.* Pharmacodynamic evaluation of ceftriaxone single-
296 dose therapy (0.125-1 g) to eradicate ceftriaxone-susceptible and ceftriaxone-resistant
297 Neisseria gonorrhoeae strains in a hollow fibre infection model for gonorrhoea. *J Antimicrob*
298 *Chemother*. 2024;79:1006–13. doi: 10.1093/jac/dkae063

299 9 Caméléna F, Mérimèche M, Brousseau J, *et al.* Emergence of Extensively Drug-Resistant
300 Neisseria gonorrhoeae, France, 2023 - Volume 30, Number 9—September 2024 - Emerging
301 Infectious Diseases journal - CDC. doi: 10.3201/eid3009.240557

302

303

304

305